FMP

FMP

Enter

RLAY - Relay Therapeutics, ...

Financial Summary of Relay Therapeutics, Inc.(RLAY), Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in tra

photo-url-https://financialmodelingprep.com/image-stock/RLAY.png

Relay Therapeutics, Inc.

RLAY

NASDAQ

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

8.9 USD

-0.08 (-0.899%)

About

ceo

Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology re...

CIK

0001812364

ISIN

US75943R1023

CUSIP

75943R102

Address

399 Binney Street

Phone

617 370 8837

Country

US

Employee

309

IPO Date

Jul 16, 2020

Summary

CIK

0001812364

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

75943R102

ISIN

US75943R1023

Country

US

Price

8.9

Beta

1.66

Volume Avg.

1.38M

Market Cap

1.18B

Shares

-

52-Week

5.7-12.71

DCF

-0.49

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-3.38

P/B

-

Website

https://www.relaytx.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest RLAY News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep